fig1

Figure 1. Overall survival in trials of first-line therapy vs. sorafenib for advanced hepatocellular carcinoma
Figure 1. Overall survival in trials of first-line therapy vs. sorafenib for advanced hepatocellular carcinoma
All published articles are preserved here permanently:
https://www.portico.org/publishers/oae/